Esperion Secures Additional Commercial And Medicare Formulary Coverage For NEXLETOL And NEXLIZET; New Additions To Medicare Formularies At Optum/United AARP And CVS/SilverScript Coupled With Humana Provides Access To More Than 65% Of Medicare Insured Lives And More Than 92% Of Commercially Insured Lives

Author: Benzinga Newsdesk | September 03, 2024 08:18am

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –

 

– Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers –

– NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Both Primary and Secondary Prevention Patients –

ANN ARBOR, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Esperion today announced that NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration's (FDA) approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives (92% of all commercial lives) and 34 million Medicare lives (65% of all Medicare lives). Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.

 

Posted In: ESPR